{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:27:20Z","timestamp":1793597240321,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cjca.2026.06.031","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:48:24Z","timestamp":1783468104000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Left Atrial Appendage Closure With Different Antithrombotic Therapies in Patients at High Bleeding Risk: A 10-Year Cohort Study"],"prefix":"10.1016","author":[{"given":"Xiaoqi","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huakang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.06.031_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.06.031_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/eurheartj\/ehs469","article-title":"All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study","volume":"34","author":"Andersson","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.06.031_bib3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.06.031_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.06.031_bib5","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.06.031_bib6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.4244\/EIJ-D-17-00672","article-title":"Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study","volume":"13","author":"Bergmann","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cjca.2026.06.031_bib7","doi-asserted-by":"crossref","first-page":"e1048","DOI":"10.1016\/j.hrthm.2025.05.048","article-title":"2025 SCAI\/HRS clinical practice guidelines on transcatheter left atrial appendage occlusion","volume":"22","author":"Goldsweig","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.06.031_bib8","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) [erratum in: 2025;46:4349]","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.06.031_bib9","first-page":"1","article-title":"Expert consensus on clinical pathway of transcatheter left atrial appendage closure in China","volume":"13","year":"2025","journal-title":"Chinese Journal of Heart and Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.06.031_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.06.031_bib11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.06.031_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2026.06.031_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.hrthm.2024.01.025","article-title":"Comparison of different direct oral anticoagulant regimens in atrial fibrillation patients with high bleeding risk","volume":"21","author":"Ciou","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.06.031_bib14","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","article-title":"Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation","volume":"50","author":"Cheng","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2026.06.031_bib15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.114.005339","article-title":"Stroke prevention in Asian patients with atrial fibrillation","volume":"45","author":"Yasaka","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2026.06.031_bib16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.06.031_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2021.02.054","article-title":"Short-term direct oral anticoagulation or dual antiplatelet therapy following left atrial appendage closure in patients with relative contraindications to chronic anticoagulation therapy","volume":"333","author":"Faroux","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2026.06.031_bib18","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jcin.2024.05.032","article-title":"Early nonprocedural bleeding after left atrial appendage occlusion","volume":"17","author":"Mesnier","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2026.06.031_bib19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1161\/CIRCULATIONAHA.125.077469","article-title":"Short-term anticoagulation versus dual antiplatelet therapy for preventing device thrombosis following left atrial appendage closure: the ANDES randomized clinical trial","volume":"152","author":"Rod\u00e9s-Cabau","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.06.031_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00380-019-01364-7","article-title":"Real-world survival data of device-related thrombus following left atrial appendage closure: 4-year experience from a single center","volume":"34","author":"Bai","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cjca.2026.06.031_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2026.06.031_bib22","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion","volume":"14","author":"Della Rocca","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2026.06.031_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/jcm12030847","article-title":"Reduced- or half-dose rivaroxaban following left atrial appendage closure: a feasible antithrombotic therapy in patients at high risk of bleeding?","volume":"12","author":"Zhou","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2026.06.031_bib24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa2513310","article-title":"Left atrial appendage closure or medical therapy in atrial fibrillation","volume":"394","author":"Landmesser","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26006537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26006537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:57:39Z","timestamp":1793595459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26006537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"alternative-id":["S0828282X26006537"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.06.031","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Left Atrial Appendage Closure With Different Antithrombotic Therapies in Patients at High Bleeding Risk: A 10-Year Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}